Search Result

Isoforms Recommended:	mGluR4

Results for "

mGlu4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Endogenous Metabolite (2) mGluR (24)
By Research Areas:	Cancer (2) Inflammation/Immunology (1) Neurological Disease (21)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100366

Lu AF21934	mGluR	Neurological Disease
Lu AF21934 is a selective and brain-penetrant *mGlu4* receptor positive allosteric modulator with an EC₅₀ of 500 nM for mGlu4 receptor .

HY-W011417

Cinnabarinic acid	Endogenous Metabolite mGluR Apoptosis	Others
Cinnabarinic acid is a specific orthosteric agonist of *mGlu₄* by interacting with residues of the glutamate binding pocket of mGlu4, has no activity at other mGlu receptors. Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway of tryptophan. Cinnabarinic acid induces cell apoptosis .

HY-15476

VU 0364439	mGluR	Neurological Disease
VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM.

HY-144698

mGlu4 receptor agonist 1	mGluR	Neurological Disease
mGlu4 receptor agonist 1 (compound 62) is a potent *mGlu4* receptor positive allosteric modulator, with an EC₅₀ of 308 nM. mGlu4 receptor agonist 1 shows significant anxiolytic- and antipsychotic-like effect .

HY-18679

TC-N 22A	mGluR	Neurological Disease
TC-N 22A is a potent, selective, orally active and brain-permeable *mGlu₄* PAM with an EC₅₀ of 9 nM in human mGlu₄-expressing BHK cells. TC-N 22A is less active (EC₅₀>10 μM) in agonist and PAM model at mGlu 1, 2, 3, 5, and 7 receptors. TC-N 22A has the potential for research of CNS disease in vivo .

HY-100841A

(S)-3-Hydroxyphenylglycine (S)-3HPG	mGluR	Neurological Disease
(S)-3-Hydroxyphenylglycine ((S)-3HPG) is a potent mGluR₁ agonist without effect at mGlu₂ or mGlu₄ .

HY-119060

FP0429	mGluR	Neurological Disease
FP0429 is a full *mGlu4* agonist and partial *mGlu8* agonist with EC₅₀ values of 48.3 μM and 56.2 μM, respectively .

HY-117450

VU0415374	Others	Others
VU0415374 is a positive allosteric modulator that modulates mGlu4 receptor activity. VU0415374 could help achieve precise light control of physiological responses. VU0415374 has high selectivity and can be used to further study the role of mGlu4 in co-expression of other mGlu receptor systems. The improved properties of VU0415374 make it an important candidate for studying mGlu4 with high precision in space and time .

HY-117764

LSP4-2022	mGluR	Neurological Disease
LSP4-2022 is a potent and brain-penetrant *mGlu4*-selective orthosteric agonist, with an EC₅₀ of 0.11 μM. LSP4-2022 inhibits neurotransmission in cerebellar slices from wild-type but not *mGlu4* receptor-knockout mice. LSP4-2022 shows pro-depressant activity .

HY-115796

VU0477886	Others	Others
VU0477886 is a metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator with potent activating activity on mGlu4 (EC₅₀ = 95nM, 89% Glu Max), good pharmacokinetic characteristics (brain: plasma Kp = 1.3), and significant therapeutic efficacy in Parkinson's disease models.

HY-100588

VU0364770	mGluR	Neurological Disease
VU0364770 is a selective and potent positive allosteric modulator (PAM) of *mGlu4. VU0346770 exhibits EC₅₀s of 290 nM and 1.1 μM at rat mGlu4* and *human mGlu4* receptor*, respectively. VU0364770 exhibits antagonist activity at mGlu5 with a potency of 17.9 μM and PAM activity at mGlu*6 with a potency of 6.8 μM. VU0364770 also possesses activity at MAO with K_i values of 8.5 and 0.72 μM for human MAO-A and human MAO-B, respectively .

HY-100588A

VU0364770 hydrochloride	mGluR	Neurological Disease
VU0364770 hydrochloride is a selective and potent positive allosteric modulator (PAM) of *mGlu4. VU0346770 hydrochloride exhibits EC₅₀s of 290 nM and 1.1 μM at rat mGlu4* and *human mGlu4* receptor*, respectively. VU0364770 hydrochloride exhibits antagonist activity at mGlu5 with a potency of 17.9 μM and PAM activity at mGlu*6 with a potency of 6.8 μM. VU0364770 hydrochloride also possesses activity at MAO with K_i values of 8.5 and 0.72 μM for human MAO-A and human MAO-B, respectively .

HY-W011417R

Cinnabarinic acid (Standard)	Endogenous Metabolite mGluR Apoptosis	Others
Cinnabarinic acid (Standard) is the analytical standard of Cinnabarinic acid. This product is intended for research and analytical applications. Cinnabarinic acid is a specific orthosteric agonist of *mGlu₄* by interacting with residues of the glutamate binding pocket of mGlu4, has no activity at other mGlu receptors. Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway of tryptophan. Cinnabarinic acid induces cell apoptosis .

HY-14419

TCN238	mGluR	Neurological Disease
TCN238 is an orally bioavailable *mGlu4* receptor positive allosteric modulator (PAM) with an EC₅₀ of 1 μM .

HY-101311

UPF-523 AIDA	mGluR	Inflammation/Immunology Cancer
UPF-523 (AIDA), a rigid (carboxyphenyl) glycine derivative, is a relatively potent and selective antagonist of group I metabotropic glutamate receptors *(mGlu1a)* with an IC₅₀ of 214 μM. But UPF-523 has no effect on group II (mGlu2), group III (mGlu4) receptors or ionotropic glutamate receptors. UPF-523 has the potential for the research of the acute arthritis .

HY-112814

VU6001376	mGluR	Neurological Disease
VU6001376 is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 4 *(mGlu4* PAM) with an EC₅₀** of 50.1 nM .

HY-100409

PHCCC	mGluR	Cancer
PHCCC is a Group I mGluR antagonist with an IC₅₀ of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect .

HY-120068

VU0418506	mGluR	Neurological Disease
VU0418506 is a selective positive allosteric modulator of *mGlu₄, with EC₅₀* values of 68 nM and 46 nM for hmGlu₄ and rmGlu₄, respectively. VU0418506 exhibits antiparkinsonian activity .

HY-103549

Z-Cyclopentyl-AP4	mGluR	Neurological Disease
Z-Cyclopentyl-AP4 is a kainate-type glutamate receptor agonist (orthosteric agonist). Z-Cyclopentyl-AP4 is more selective for *mGlu4* than mGlu8 .

HY-120567

VU0400195 ML182	mGluR	Neurological Disease
VU0400195 (ML182) is a oral active and allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4) with the EC₅₀ of 291 nM. VU0400195 can be used for study of antiparkinsonian animal model .

HY-100781A

L-AP4 L-APB	mGluR	Neurological Disease
L-AP4 (L-APB) is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

HY-100781B

L-AP4 monohydrate L-APB monohydrate	mGluR	Neurological Disease
L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

HY-70059

LY341495 Maximum Cited Publications 10 Publications Verification	mGluR	Neurological Disease
LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC₅₀s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively .

HY-122647

Valiglurax VU0652957; VU2957	mGluR	Neurological Disease
Valiglurax (VU0652957) is a potent, orally active and selective mGlu4 positive allosteric modulator with EC₅₀ values of 64.6 nM and 197 nM for hmGlu₄/Gqi5 and rmGlu₄ GIRK, respectively. Valiglurax is a central nervous system (CNS) penetrant. Valiglurax can be used in research of Parkinson's disease .

HY-70059A

(Rac)-LY341495	Others	Neurological Disease
(Rac)-LY341495 is the isomer of LY341495 (HY-70059), and can be used as an experimental control. LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC₅₀s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively .

HY-101335

DCG-IV	mGluR	Neurological Disease
DCG-IV is a potent agonist of group II mGluRs with EC₅₀s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC₅₀: mGlu1R/5R=389/630 μM) and III receptors (IC₅₀: mGlu4R/6R/7R/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects .

HY-167899

PXT-012253	mGluR	Neurological Disease
PXT-012253 is a positron emission tomography (PET) ligand for *mGluR4*, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

mGlu4

Inhibitors & Agonists